To identify an EPHB4 inhibitor with a potential of rapid translation into clinic, we screened a pool of clinically approved compounds using hematologic cancer cells expressing different levels of EPHB4. The gene discussed is EPHB4; the disease is hematopoietic and lymphoid cell neoplasm.